Biotech just walked into the policy spotlight, with BIO’s new BioAdvance blueprint putting faster trials, friendlier regulation and bigger federal research budgets on the table. That kind of attention can shift how capital flows, which means investors risk missing the early moves if they wait for the dust to settle. This article introduces 3 U.S.-listed biotech stocks that are directly exposed to this policy story and explains why that matters in the current environment.
The three stocks covered below are just a sample, and the broader screen surfaced 51 more U.S.-listed biotechnology companies with similarly rich stories across gene and cell therapy, antibodies and small molecule platforms that are not discussed here. To spot ideas that fit your own risk tolerance and timing, head straight into the U.S.-listed Biotechnology Stocks screener to filter, analyze and identify the biotech setups that match your highest conviction.
Biogen (BIIB)
Overview: Biogen is a U.S.-listed biotechnology group focused on central nervous system and neurological diseases, using antibodies and other drug modalities to develop and commercialize therapies worldwide.
Operations: Biogen reports about US$10.3b from discovering, developing and delivering therapies, with roughly US$6.3b recorded in the United States and the balance through segment adjustments.
Market Cap: US$36.7b
Biogen matters for this U.S.-listed Biotechnology Stocks theme because it sits where policy, clinical trial design and complex neurology drugs all intersect, and the analyst consensus Narrative on Simply Wall St describes how that mix shapes expectations for its next phase.
"Expansion of the Alzheimer’s franchise through LEQEMBI IQLIK in the US and LEQEMBI Pen in Japan, both once-weekly subcutaneous options for at-home administration, is expected to make treatment more accessible and convenient, which can widen the treated population and support higher long-term revenue and operating leverage."
What happens to Biogen’s earnings profile if a single pressure on its broader neurology pipeline plays out differently than consensus assumes?
If that earnings swing matters to your thesis, read the full narrative for Biogen to see how those pipeline scenarios could be accelerating or quietly stalling Biogen’s story.
Gilead Sciences (GILD)
Overview: Gilead Sciences is a large U.S.-listed biopharmaceutical group that researches, develops and sells antiviral, oncology and immunology therapies closely tied to U.S. biotech regulation.
Operations: Gilead generates about US$31b from discovering, developing and commercializing medicines, including roughly US$22.8b in the United States and US$4.8b in Europe.
Market Cap: US$207b
Gilead Sciences sits right where the BioAdvance policy blueprint is aimed, with a heavy U.S. R&D footprint and a portfolio that lives or dies on how regulators treat complex biologics, which is exactly why kapirey, an investor in the Simply Wall St Community, frames the story through one flagship program.
"Lenacapavir: First twice‑yearly HIV PrEP injectable; structural shift from daily oral to long‑acting → large TAM expansion and a key driver of HIV growth into the next decade"
What happens to Gilead’s cash generation and balance sheet flexibility if a single policy shift around long-acting HIV prevention changes pricing power.
That kind of policy shock can flip the script fast. Read the full narrative for Gilead Sciences to see how Gilead Sciences could be accelerating or stalling beneath the headlines.
Vertex Pharmaceuticals (VRTX)
Overview: Vertex Pharmaceuticals develops specialty medicines for serious diseases such as cystic fibrosis, sickle cell disease, beta thalassemia, kidney disorders and pain.
Operations: Vertex Pharmaceuticals generates about US$13b from pharmaceuticals, with around US$8.1b in the United States and US$3.8b in Europe.
Market Cap: US$138.7b
Vertex Pharmaceuticals is a pure-play biotech tied closely to U.S. drug policy. The analyst consensus Narrative on Simply Wall St highlights how its expanding portfolio of cell, gene and small molecule programs aligns with the kind of FDA and NIH support BioAdvance is trying to promote.
"Expansion of the renal disease portfolio, including late stage programs like povetacicept in IgA nephropathy with what management describes as best in class numerical reductions in proteinuria and favorable auto injector dosing, and inaxaplin in APOL1 mediated kidney disease with significant UACR reductions and an interim 1 year eGFR readout planned in early 2027, is supported by growing regulatory acceptance of proteinuria and 1 year eGFR endpoints."
The real swing factor is what happens to that carefully built earnings profile if one key regulatory assumption in this toolkit shifts unexpectedly.
If that kind of policy jolt is on your mind, read the full narrative for Vertex Pharmaceuticals to see where Vertex Pharmaceuticals could be accelerating or quietly decoupling expectations.
Seeking Alternatives Before The Crowd?
Fresh ideas move first. Breakout themes gather momentum while screens are still quiet and under the radar for now. Do not get caught reacting late; consider acting earlier.
- Track stronger balance sheets before momentum goes flying by using the list of solid balance sheet and fundamentals (25 results), which highlights companies with sturdier finances while it still matters.
- Target income plays that could keep paying even when markets wobble through the 6 dividend fortresses, curated for yield-focused investors who want to avoid chasing dropping payouts.
- Hunt for potential infrastructure participants in AI-related activity with the 53 AI infrastructure stocks, while many of these operators remain under the radar for now.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com